The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated pancreatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback